The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast
Early Phase 1
- Conditions
- Healthy
- Interventions
- Device: Soctec
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 15
- Registration Number
- NCT02335515
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 64
- Registration Number
- NCT00830102
- Locations
- 🇬🇧
Investigational site, Slough, United Kingdom
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: SKP FlutiForm HFA pMDI
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 280
- Registration Number
- NCT00747318
- Locations
- 🇺🇦
Investigational site, Zaporizhzhya, Ukraine
🇲🇽Investigational Site, Zapopan, Zapopan Jalisco, Mexico
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
Phase 2
Completed
- Conditions
- Mild to Moderate Asthma
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 39
- Registration Number
- NCT00734292
- Locations
- 🇺🇸
Investigational Site, West Allis, Wisconsin, United States
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 160
- Registration Number
- NCT00657774
- Locations
- 🇺🇸
Investigational Site, Lake Oswego, Oregon, United States
🇺🇸Investigational site, San Antonio, Texas, United States
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 438
- Registration Number
- NCT00649025
- Locations
- 🇺🇸
Investigational site, Richmond, Virginia, United States
🇺🇦Investigational Site, Zaporizhzhya, Ukraine
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 475
- Registration Number
- NCT00393991
- Locations
- 🇺🇸
Research Center, Elizabeth City, North Carolina, United States
🇨🇦Research Site, St. John's, Canada
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 357
- Registration Number
- NCT00394199
- Locations
- 🇨🇦
Research Site, Trois Rivieres, Quebec, Canada
🇨🇦Research Center, London, Ontario, Canada
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 557
- Registration Number
- NCT00393952
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇵🇷Research Center, Ponce, Puerto Rico
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- SkyePharma AG
- Target Recruit Count
- 400
- Registration Number
- NCT00394121
- Locations
- 🇬🇧
Research Site, Swindon Wilts, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath